An interventional study of Empowered Relief and Living Better with Chronic Pain in Crohn's Disease, Ulcerative Colitis (UC) and Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), sponsored by Cedars-Sinai Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Crohn Disease by Cedars-Sinai Medical Center — 2 open to participants now, 2 under way, none of them phase 3. Crohn Disease · Cedars-Sinai Medical Center.
Among the 10 studies in Crohn Disease by Cedars-Sinai Medical Center, this one is the only one that started in 2026, is one of 4 with no phase, and was the 10th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →2 of the 10 studies in Crohn Disease by Cedars-Sinai Medical Center are open now, in 1 country. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 13–28
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 47 across the 8 interventional studies, 38 across the 2 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
2 of the studies in Crohn Disease by Cedars-Sinai Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07671313Cedars-Sinai Medical CenterOnline Pain Education for Crohn's Disease and Ulcerative Colitis | 2027-07 |
| NCT04224558Cedars-Sinai Medical CenterStem Cell Transplantation in Crohn's Disease | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Crohn Disease by Cedars-Sinai Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take up to 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Medically stable, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the Empowered Relief arm will be scheduled to attend a 2-hour, live-online group Empowered Relief session. Empowered Relief sessions will be conducted via Zoom. Attendance of the Empowered Relief session will be monitored by study staff throughout the 2-hour session. Following the Empowered Relief session, participants in this arm will be provided with access to the 20-minute binaural audio relaxation app the that accompanies the Empowered Relief program and promotes calm through brainwave entrainment. Participants will be instructed to utilize the binaural audio app daily for the 8-weeks following the completion of the Empowered Relief session.
Behavioral: Empowered Relief
Living Better with Chronic Pain provides education on: (i) chronic pain mechanisms, (ii) nutrition and weight management, (iii) physical activity, (iv) working with healthcare providers, (v) informed treatment decisions, and (vi) medication safety. Participants randomized to the Living Better with Chronic Pain arm will be sent a link to access the \~1-hour online recording. Completion of the entire Living Better with Chronic Pain video will be monitored and confirmed by study staff.
Behavioral: Living Better with Chronic Pain
Empowered Relief is an online pain education program. Empowered Relief 'compresses' key cognitive behavioral therapy skills, mindfulness principles, and pain neuroscience education into a highly pragmatic, scalable, single 2-hour session. Taught via Zoom by certified instructors to large groups of patients, it teaches participants to identify unhelpful pain-related thoughts, manage physiological hyperarousal, and build coping skills through cognitive reframing, guided relaxation, and self-soothing techniques. Participants receive a 20-minute binaural audio relaxation app that promotes calm through brainwave entrainment.
Living Better with Chronic Pain is a 2-hour online health program that provides education regarding chronic pain mechanisms, nutrition and weight management, physical activity, working with healthcare providers, informed treatment decisions, and medication safety.
PROMIS Pain Interference
Pain interference as measured by the validated 8-item PROMIS Pain Interference (PROMIS-PI) scale. It assesses self-reported consequences of pain on relevant aspects of one's life, including the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. This instrument is universal, rather than disease-specific. The recall period for this scale is 7 days.
Time frame: Baseline, then weekly post-treatment (Weeks 1-8)
PROMIS Pain Intensity
Pain intensity as measured by the validated 1-item PROMIS Pain Intensity Numeric Rating Scale (NRS). It asks how one would rate their pain on average over the last 7 days, on a scale of 0 to 10.
Time frame: Baseline, then weekly post-treatment (Weeks 1-8)
PROMIS Abdominal Pain
Abdominal pain as measured by the validated 5-item PROMIS Abdominal Pain scale. PROMIS Abdominal Pain assesses the severity of belly pain over the past 7 days. This instrument is universal, rather than disease-specific.
Time frame: Baseline, then weekly post-treatment (Weeks 1-8)
Pain Catastrophizing Scale
Pain catastrophizing as measured by the validated 13-item Pain Catastrophizing Scale (PCS). It assesses the types of thoughts and feeling that one has when in pain. This scale does not have a specified recall period, but asks for one to review various statements describing different thoughts and feelings that may be associated with pain, and respond based on when experiencing pain previously.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
Pain Self-Efficacy
Pain self-efficacy as measured by the validated 10-item Pain Self-Efficacy Questionnaire (PSEQ). This scale does not have a specified recall period, but asks for one to rate on a scale of 0 to 6 how confident they are that they can do various things at present, despite the pain.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
Inflammatory Bowel Disease Disability Index
The Inflammatory Bowel Disease Disability Index is a validated, disease-specific measure that assesses the impact of Crohn's disease and ulcerative colitis on daily functioning, including physical health, body functions, activities, participation, and overall disability.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
IBD Control Questionnaire
IBD symptoms as measured by the validated 8-item and 1-question visual analog scale (VAS) IBD Control questionnaire. It assesses perceived control over symptoms, usefulness of current treatment, and impact of IBD on various domains over the past 2 weeks.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
Pain Location Assessment
Pain location as measured by a 1-item Pain Location Assessment questionnaire which asks one to select from a list all of the locations on the body where they have experienced pain in the last 7 days.
Time frame: Baseline, then weekly post-treatment (Weeks 1-8)
PROMIS Sleep Disturbance
Sleep disturbance as measured by the validated 4-item PROMIS Sleep Disturbance questionnaire. It assesses self-reported perceptions of sleep quality, sleep process, and restoration associated with sleep. The recall period for this scale is 7 days.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
PROMIS Anxiety
Perceived anxiety as measured by the the validated 8-item PROMIS Emotional Distress - Anxiety scale. It assesses self-reported fear, anxious misery, and hyperarousal. The recall period for this scale is 7 days.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
PROMIS Depression
Perceived depression as measured by the the validated 8-item PROMIS Emotional Distress - Depression scale. It assesses self-reported negative mood, views of self, and social cognition. The recall period for this scale is 7 days.
Time frame: Baseline, then at Weeks 4 and 8 post-treatment
Treatment Appraisal and Satisfaction
Treatment appraisal and satisfaction as measured by a 20-item Treatment Appraisal and Satisfaction Survey. It assess usability, relevance, usefulness, and how likely one is to recommend the program to others.
Time frame: Day 1 post-treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 8 months is below that.
Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.
Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.